Phthisiology at the dawn of the new century: A review of tuberculosis and the prospects for its elimination

Chest

Volumn 117, Issue 5, 2000, Pages 1455-1473

  Lauzardo, Michael ^a,b   Ashkin, David ^a,c  

^a FLORIDA DEPARTMENT OF HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Epidemiology; Mycobacterium tuberculosis; Phthisiology; Review; Therapy; Tuberculosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIMYCOBACTERIAL AGENT; BCG VACCINE; BETA LACTAM DERIVATIVE; GAMMA INTERFERON; IMIPENEM; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MEROPENEM; METRONIDAZOLE; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STEROID; TUBERCULIN;

CLINICAL FEATURE; CLINICAL PROTOCOL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTHERAPY; INCIDENCE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUBERCULIN TEST; TUBERCULOSIS CONTROL;

EID: 0034091106     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.5.1455     Document Type: Review

References (166)

1. 1 Lister J. Professor Koch's remedy for tuberculosis. BMJ 1890; 2:1372-1374
2. 2 Thomas HM. Prevention of tuberculosis. JAMA 1900; 34: 714-719
3. 3 Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72:213-220
4. 4 Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis. JAMA 1995; 273:220-226
5. 5 Styblo K. The relationship between the risk of tuberculosis infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc Lung Dis 1986; 60:117-119
6. 6 Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992; 70:149-159
7. 7 Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273:220-226
8. 8 Chin J. Global estimates of AIDS cases and HIV infections: 1990. AIDS 1990; 4(suppl):S227-S283
9. 9 Chum HJ, O'Brien RJ, Chonde TM, et al. An epidemiologic study of tuberculosis and HIV infection in Tanzania, 1992-1993. AIDS 1996; 10:299-309
10. 10 Richards SB, St. Louis ME, Niegurg P, et al. Impact of the HIV epidemic on trends in tuberculosis in Abidjan, Cote d'Ivoire. Tubercle Lung Dis 1995; 76:11-16
11. 11 Lindan CP, Lieu TX, Giang LT, et al. Rising HIV infection rates in Ho Chi Minh City herald emerging AIDS epidemic in Vietnam. AIDS 1997; 11(suppl 1):S5-S13
12. 12 Pais P. HIV and India: looking into the abyss. Trop Med Int Health 1996; 1:295-304
13. 13 Murray CJ, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65:6-24
14. 14 Yanai H, Uthaivoravit W, Panich V, et al. Rapid increase in HIV related tuberculosis, Chiang Rai, Thailand 1990-1994. AIDS 1996; 10:527-531
15. 15 Raviglione MC, Sudre P, Rieder HL, et al. Secular trends of tuberculosis in western Europe. Bull World Health Organ 1993; 71:297-306
16. 16 Centers for Disease Control and Prevention. Tuberculosis: United States, first 39 weeks. MMWR Morb Mortal Wkly Rep 1985; 1985:34:625-627
17. 17 Centers for Disease Control and Prevention. Tuberculosis morbidity: United States. MMWR Morb Mortal Wkly Rep 1997; 1996:46:695-700
18. 18 World Health Organization. Anti-tuberculosis drug resistance in the world. Geneva: World Health Organization, 1997
19. 19 TB and Airborne Disease Weekly, Sept. 1998, 28
20. 20 Raviglione MC, Rieder HL, Styblo K, et al. Tuberculosis trends in eastern Europe and the former USSR. Tubercle Lung Dis 1994; 75:400-416
21. 21 Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV infected persons. JAMA 1995; 274:143-148
22. 22 Levine VR. Epidemiology of AIDS and tuberculosis among United States veterans. Int J Tuberc Lung Dis 1998; 2:405-412
23. 23 Centers for Disease Control and Prevention. Tuberculosis morbidity: United States, 1995. MMWR Morb Mortal Wkly Rep 1996; 45:366-370
24. 24 Mayans MV, Maguire A, Miret M, et al. The spread of AIDS and the re-emergence of tuberculosis in Catalonia Spain. AIDS 1997; 11:499-505
25. 25 Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV infected persons. Ann Intern Med 1997; 126:123-132
26. 26 Asch SM, London AS, Barnes PF, et al. Testing for human immunodeficiency virus infection among tuberculosis patients in Los Angeles. Am J Respir Crit Care Med 1997; 155:378-381
27. 27 Centers for Disease Control and Prevention. Recommendations for prevention and control of tuberculosis among foreign-born persons. MMWR Morb Mortal Wkly Rep 1998; 47(RR-16):1-26
28. 28 Heath TC, Roberts C, Winks M, et al. The epidemiology of tuberculosis in New South Wales 1975-1995: the effect of immigration on a low prevalence population. Int J Tuberc Lung Dis 1998; 8:647-654
29. 29 Wang JS, Allen EA, Enarson DA, et al. Tuberculosis in recent Asian immigrants to British Columbia, Canada: 1982-1985. Tubercle 1991; 72:277-283
30. 30 Tornieporth NG, Ptachewich Y, Poltoratskaia BS, et al. Tuberculosis among foreign-born persons in New York City, 1992-1994: implications for tuberculosis control. Int J Tuberc Lung Dis 1997; 1:528-535
31. 31 Jasmer RM, Ponce de Leon A, Hopewell PC, et al. Tuberculosis in Mexican-born persons in San Francisco: reactivation, acquired infection, and transmission. Int J Tuberc Lung Dis 1997; 1:536-541
32. 32 Zuber PL, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997; 278:304-307
33. 33 Enarson DA, Ashley MJ, Grzybowski S. Tuberculosis in immigrants to Canada. Am Rev Respir Dis 1979; 119:11-18
34. 34 Enarson DA, Sjogren I, Grzybowski S. Tuberculosis in immigrants to Canada: incidence of tuberculosis among Scandinavian immigrants in Canada. Eur J Respir Dis 1980; 61:139-142
35. 35 Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. N Engl J Med 1994; 330:1703-1709
36. 36 Ussery XT, Valway SE, McKenna M, et al. Epidemiology of tuberculosis among children in the United States: 1985-1994. Pediatr Infect Dis J 1996; 15:697-704
37. 37 Binkin NJ, Zuber PL, Wells CD, et al. Overseas screening for tuberculosis in immigrants and refugees to the United States: current status. Clin Infect Dis 1996; 23:1226-1232
38. 38 Cantwell MF, McKenna MT, McCray E, et al. Tuberculosis and race/ethnicity in the United States. Am J Respir Crit Care Med 1997; 157:1016-1020
39. 39 Funnye AS, Ganesan K, Yoshikawa TT. Tuberculosis in African-Americans: clinical characteristics and outcome. J Natl Med Assoc 1998; 90:73-76
40. 40 Rosenman KD, Hall N. Occupational risk factors for developing tuberculosis. Am J Ind Med 1996; 30:148-154
41. 41 Barnes PF, El-Hajj H, Preston-Martin S, et al. Transmission of tuberculosis among the urban homeless. JAMA 1996; 275:305-307
42. 42 Daley CL, Hahn JA, Moss AR, et al. Incidence of tuberculosis in injection drug users in San Francisco. Am J Respir Crit Care Med 1998; 157:19-22
43. 43 Miller B, Rosenbaum S, Stange PV, et al. Tuberculosis control in a changing health care system. Clin Infect Dis 1998; 27:677-686
44. 44 Harris JR, Gordon RL, White KE, et al. Prevention and managed care: opportunities for managed care organizations, purchasers of health care and public health agencies. MMWR Morb Mortal Wkly Rep 1995; 44(RR-14):1-27
45. 45 Halverson PK, Mays GP, Miller CA, et al. Managed care and the public health challenge of TB. Public Health Rep 1997; 112:22-28
46. 46 Behr MA, Small PM. Molecular fingerprinting of Mycobacterium tuberculosis: how it can help the clinician. Clin Infect Dis 1997; 25:806-810
47. 47 Van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting. J Clin Microbiol 1993; 31:406-409
48. 48 Samper S, Iglesias MJ, Rabanaque MJ, et al. The molecular epidemiology of tuberculosis in Zaragoza, Spain. Int J Tuberc Lung Dis 1998; 2:281-287
49. 49 Alland D, Kalkut GE, Moss A, et al. Transmission of tuberculosis in New York City. N Engl J Med 1994; 330:1710-1716
50. 50 Yang ZH, De Haas PE, Wachmann CH, et al. Molecular epidemiology of tuberculosis in Denmark in 1992. J Clin Microbiol 1995; 33:2077-2081
51. 51 Jasmer RM, Hahn JA, Small PM, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999; 130;971-978
52. 52 Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear negative for acid-fast bacilli. Lancet 1999; 353:444-449
53. 53 Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmission of multi-drug resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment polymorphism analysis. J Infect Dis 1993; 168: 1052-1055
54. 54 Pearson ML, Jereb JA, Frieden TR, et al. Nosocomial transmission of multi-drug resistant Mycobacterium tuberculosis: a risk to patients and healthcare workers. Ann Intern Med 1992; 117:191-196
55. 55 Lemaitre N, Sougakoff W, Truffot-Pernot C, et al. Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers. Int J Tuberc Lung Dis 1998; 2:390-396
56. 56 Beck-Sague CM, Dooley SW, Hutton MD, et al. Hospital outbreak of multi-drug resistant Mycobacterium tuberculosis infections: factors in transmission to staff and HIV infected patients. JAMA 1992; 268:1280-1286
57. 57 Burman WJ, Stone BL, Reves RR, et al. The incidence of false positive cultures for Mycobacterium tuberculosis. Am J Respir Crit Care Med 1997; 155:321-326
58. 58 Agerton T, Valway S, Gore B, et al. Transmission of a highly drug-resistant strain (strain W1) of Mycobacterium tuberculosis. JAMA 1997; 278:1073-1077
59. 59 Kline SE, Hedemark LL, Davies SF. Outbreak of tuberculosis among regular patrons of a neighborhood bar. N Engl J Med 1995; 333:222-227
60. 60 Mangura BT, Napololitano EC, Passannante MR, et al. Mycobacterium tuberculosis miniepidemic in a church gospel choir. Chest 1998; 113:234-237
61. 61 Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction fragment length polymorphisms. N Engl J Med 1992; 326:231-235
62. 62 Valway SE, Sanchez MP, Shinnick TF, et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 1998; 338:633-639
63. 63 Hermans PW, Messadi F, Guebrexabher H, et al. Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia, and the Netherlands: usefulness of DNA typing for global tuberculosis epidemiology. J Infect Dis 1995; 171:1504-1513
64. 64 Wilkinson D, Pillay M, Crump J, et al. Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in rural Africa. Trop Med Int Health 1997; 2:747-753
65. 65 Namwat W, Luangsuk P, Palitta Pongarnpim P. The genetic diversity of Mycobacterium tuberculosis strains in Thailand studied by amplification of DNA segments containing direct repetitive sequences. Int J Tuberc Lung Dis 1998; 2:153-159
66. 66 Pineda-Garcia L, Ferrera A, Hoffner S. DNA fingerprinting of Mycobacterium tuberculosis strains from patients with pulmonary tuberculosis in Honduras. J Clin Microbiol 1997; 35:2393-2397
67. 67 Yang Z, Barnes PF, Chaves F, et al. Diversity of DNA fingerprints of Mycobacterium tuberculosis isolates in the United States. J Clin Microbiol 1998; 36:1003-1007
68. 68 Genewein A, Telent A, Bernasconi C, et al. Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet 1993; 342:841-844
69. 69 Van Soolingen D, Qian L, De Haas PE, et al. Predominance of a single genotype of Mycobacterium tuberculosis in countries of East Asia. J Clin Microbiol 1995; 33:3234-3238
70. 70 Yeh RW, Ponce De Leon A, Agasino CB, et al. Stability of Mycobacterium tuberculosis DNA genotypes. J Infect Dis 1998; 177:1107-1111
71. 71 Agasino CB, Ponce De Leon A, Jasmer RM, et al. Epidemiology of Mycobacterium tuberculosis strains in San Francisco that do not contain IS6110. Int J Tuberc Lung Dis 1998; 2:518-520
72. 72 Braden CR, Templeton GL, Cave MD, et al. Interpretation of restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from a state with a large rural population. J Infect Dis 1997; 175:1446-1452
73. 73 Molloy A, Kaplan G. Cell-mediated immune response. In: Rom WN, Garay S, eds. Tuberculosis. Boston, MA: Little, Brown Company, 1996; 305-314
74. 74 Grzybowski S, Barnett GD, Stylbo K. Contacts of cases of active tuberculosis. Bull Int Union Tuberc 1975; 50:90-106
75. 75 Marcy SM, Kibrick S. Measles. In: Hoeprich PD, ed. Infectious diseases. New York, NY: Harper Row, 1977; 691-700
76. 76 Riley RL, Mills CC, O'Grady F, et al. Infectiousness of air from a tuberculosis ward: comparative infectiousness of different patients. Am Rev Respir Dis 1962; 84:511-525
77. 77 Zhang M, Gong J, Yang Z, et al. Enhanced capacity of a widespread strain of Mycobacterium tuberculosis to grow in human macrophages. J Infect Dis 1999; 179:1213-1217
78. 78 Rich AR. The pathogenesis of tuberculosis, 2nd ed. Springfield, IL: Charles C. Thomas, 1951; 664
79. 79 Stead WW. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Am Rev Respir Dis 1967; 95:729-745
80. 80 Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ 1977; 2:293-295
81. 81 Garay SM. Pulmonary tuberculosis. In: Rom WN, Garay S, eds. Tuberculosis. Boston, MA: Little, Brown Company, 1996; 395-399
82. 82 Toosi Z, Kleinherz ME, Ellner JJ. Defective IL-2 production and responsiveness in human tuberculosis. J Exp Med 1986; 163:1162-1172
83. 83 Krause AK. A few observations on immunity to tuberculosis. Am Rev Respir Dis 1922; 19:306-308
84. 84 Goodwin RA, Des Prez RM. Apical localization of pulmonary tuberculosis, chronic pulmonary histoplasmosis and progressive massive fibrosis of the lung. Chest 1983; 83:801-805
85. 85 Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64:2062-2069
86. 86 Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998; 6:107-112
87. 87 Schluger NW, Rom WN. Current approaches to the diagnosis of active pulmonary tuberculosis. Am J Respir Crit Care Med 1994; 149:264-267
88. 88 Levy H, Feldman C, Sacho H, et al. A reevaluation of sputum microscopy and culture in the diagnosis of pulmonary tuberculosis. Chest 1989; 95:1193-1197
89. 89 Catanzaro A, Davidson BL, Fujiwara PI, et al. Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med 1997; 155:1804-1814
90. 90 Condos R, McClune A, Rom WN, et al. Peripheral-blood-based PCR assay to identify patients with active pulmonary tuberculosis. Lancet 1996; 347:1082-1085
91. 91 Shanker P, Manjunath N, Mohan KK, et al. Rapid diagnosis of tuberculosis meningitis by polymerase chain reaction. Lancet 1991; 337:5-7
92. 92 Telenti A, Lowrie D, Matter L, et al. Detection of rifampacin-resistant mutations in Mycobacterium tuberculosis. Lancet 1993; 341:617-620
93. 93 Cole ST. Mycobacterium tuberculosis: drug resistance mechanisms. Trends Microbiol 1994; 2:411-415
94. 94 Head SR, Parik K, Rogers Y, et al. Solid-phase sequence scanning for drug resistance detection in tuberculosis. Mol Cell Probes 1999; 13:81-87
95. 95 Hellyer TJ, DesJardin LE, Teixeira L, et al. Detection of viable Mycobacterium tuberculosis by reverse transcriptase-strand displacement amplification of mRNA. J Clin Microbiol 1999; 37:518-523
96. 96 Dubos R, Dubos J. The white plague. New Brunswick, NJ: Rutgers University Press 1952; 106
97. 97 Mantoux C. L'intradermo-reaction a la tuberculin et son interpretation clinique. Presse Med 1910; 18:10-13
98. 98 Furcolow ML. Quantitative studies of the tuberculin reaction: I. Titration of tuberculin sensitivity and its relationship to tuberculous infection. Public Health Rep 1941; 56:1082-1100
99. 99 Stead WW. The face of tuberculosis. Hosp Pract 1969; 4:62-68
100. 100 Kimura M, Converse PJ, Astemborski J, et al. Comparison between a whole blood interferon-γ release assay and tuberculin skin testing for the detection of tuberculous infection among patients at risk for tuberculosis exposure. J Infect Dis 1999; 179:1297-1300
101. 101 Centers for Disease Control and Prevention. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR 1997; 46(RR-15):1-10
102. 102 Halsey NA, Coberly JS, Desormeaux J et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351:786-792
103. 103 Gordin F, Chaisson R, Matts J, et al. A randomized trial of two months of rifampin and pyrazinamide versus twelve months of isoniazid for the prevention of tuberculosis in HIV-positive PPD positive patients [abstract]. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 1998
104. 104 Cantwell MF, Snider DE, Cauthen GM, et al. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 272:535-539
105. 105 Granich R, Zuber PL, McMillan M, et al. Tuberculosis among foreign-born residents of southern Florida, 1995. Public Health 1998; 113:552-556
106. 106 McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986-1993. N Engl J Med 1995:332:1071-1076
107. 107 Perrins JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144:750-755
108. 108 Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324:289-294
109. 109 Pitchenik AE, Rubinson HA. The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis 1985; 131:393-396
110. 110 Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression: the Terry Beirn Community Programs for Clinical Research on AIDS (CPRCA). Clin Infect Dis 1997; 25:242-246
111. 111 Jones BE, Ryu R, Yang Z, et al. Chest radiographic findings in patients with tuberculosis with recent or remote infection. Chest 1997; 156:1270-1273
112. 112 Leung AN, Brauner MW, Gamsu G, et al. Pulmonary tuberculosis: comparison of CT findings in HIV seropositive and HIV seronegative patients. Radiology 1996; 198:687-691
113. 113 Greenberg SD, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings. Radiology 1994; 193:115-119
114. 114 Molla A, Korneyva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-766
115. 115 Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171:537-545
116. 116 Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367-373
117. 117 Perucca E, Grimaldi R, Frigoo GM, et al. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988; 34:595-599
118. 118 Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: a single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tubercle Lung Dis 1995; 76:210-218
119. 119 Stambaugh JJ, Narita M, Ibrahim E, et al. Use of rifabutin (RBT) with protease inhibitors (PIs) for HIV-infected TB patients [abstract]. Paper presented at: Sixth Conference on Retroviruses and Opportunistic Infections; February 2, 1999; Chicago, IL Abstract 449
120. 120 Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with HIV: principles of therapy and revised recommendations. MMWR 1998; 47(RR-20):1-58
121. 121 Centers for Disease Control and Prevention. Report of the NIH panel to define principals of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 47(RR-5):1-63
122. 122 Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-161
123. 123 Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-550
124. 124 Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119:189-193
125. 125 Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at a high risk for tuberculosis. N Engl J Med 1997; 337:315-320
126. 126 Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521-526
127. 127 Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 1997. Washington, DC: US Department of Health and Human Services, Public Health Service, 1998
128. 128 Loveday C, Devereaux H, Huckett L, et al. High prevalence of multi drug resistance mutations in a UK HIV/AIDS patient population. AIDS 1999; 13:627-628
129. 129 Davidson BL. A controlled comparison of directly observed therapy vs self-administered therapy for active tuberculosis in the urban United States. Chest 1998; 114:1239-1243
130. 130 Zwarenstein M, Schoeman JH, Vundule C, et al. Randomised controlled trial of self supervised and directly observed treatment of tuberculosis. Lancet 1998; 352:1340-1343
131. 131 Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV related tuberculosis treated with once-weekly rifapentine and isoniazid: Tuberculosis Trials Consortium. Lancet 1999; 353:1843-1847
132. 132 World Health Organization. The TB treatment [editorial]. Observer March 24, 1997
133. 133 Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155:1595-1600
134. 134 Gunnels JJ, Bates JH, Swindoll H. Infectivity of sputum-positive tuberculosis patients on chemotherapy. Am Rev Respir Med 1974; 109:323-330
135. 135 LoBue PA, Cass R, Lobo D, et al. Development of housing programs to aid in the treatment of tuberculosis in homeless individuals: a pilot study. Chest 1999; 115:218-223
136. 136 Ellner JJ. Review: the immune response in human tuberculosis: implications for tuberculosis control. J Infect Dis 1997; 176:1351-1359
137. 137 Aronson JD, Aronson CF, Taylor HC. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. Arch Intern Med 1958; 101:881-893
138. 138 Aronson JD. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc 1948; 58:275-276
139. 139 Rosenthal SR, Loewinsohn E, Graham ML, et al. BCG vaccination against tuberculosis in Chicago. Pediatrics 1961; 28:622-641
140. 140 Comstock GW, Webster RG. Tuberculosis studies in Muscogee County, Georgia: a twenty-year study of BCG vaccination in a school population. Am Rev Respir Dis 1969; 100:839-845
141. 141 Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia: a twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep 1976; 91:276-280
142. 142 Tuberculosis Prevention Trial, Madras. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J Med Res 1980; 72(suppl):1-74
143. 143 Ferguson RG, Simes AB. BCG vaccination of Indian infants in Saskatchewan. Tubercle 1949; 30:5-11
144. 144 Wunsch Filho M, de Castilho EA, Rodrigues LC, et al. Effectiveness of BCG vaccination against tuberculous meningitis: a case control study in Sao Paulo, Brazil. Bull World Health Organ 1990; 68:69-74
145. 145 Packe GE, Innes JA. Protective effect of BCG vaccination in infant Asians: a case-control study. Arch Dis Child 1988; 63:277-281
146. 146 Young TK, Hershfield ES. A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians. Am J Public Health 1986; 76:783-786
147. 147 TenDam HG, Hitze KL. Does BCG vaccination protect the newborn and young infants? Bull World Health Organ 1980; 58:37-41
148. 148 Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271:698-702
149. 149 Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393:537-544
150. 150 Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998; 2:971-978
151. 151 Lozes E, Huygen K, Content J, et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 1997; 15:830-833
152. 152 Ulmer JB, Liu MA, Montgomery DL, et al. Expression and immunogenicity of M tuberculosis antigen 85 by DNA vaccination. Vaccine 1997; 15:792-794
153. 153 Lowrie DB, Silva CL, Colston MJ, et al. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 1997; 15:834-838
154. 154 Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 8:893-898
155. 155 Centers for Disease Control and Prevention. Development of new vaccines for tuberculosis. MMWR Morb Mortal Wkly Rep 1998; 47(RR-13):1-6
156. 156 Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154:1034-1038
157. 157 Kochi A. Tuberculosis control: is the DOTS the health breakthrough of the 1990s? World Health Forum 1997; 18:225-247
158. 158 Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998; 2:265-271
159. 159 Tsukamura M, Nakamura E, Yoshii S, et al. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985; 131: 352-356
160. 160 Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin, and rifampicin. Tubercle Lung Dis 1992; 73:59-67
161. 161 Nadler JP, Berger J, Nord JA, et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99:1025-1026
162. 162 Edwards JR., WB, Rayner A, et al. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tubercle Lung Dis 1992; 73:134-136
163. 163 Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38:2054-2058
164. 164 Barry CE. New horizons in the treatment of tuberculosis. Biochem Pharmacol 1997; 54:1165-1172
165. 165 Jeevan A, Asherson GL. Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice. Infect Immun 1988; 56:660-664
166. 166 Chan J, Xing Y, Magliozo, Bloom BR. Killing of Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophage. J Exp Med 1992; 175:111-112